Sugi Predict

Sugi Predict / Compounds / SCHEMBL30923959

SCHEMBL30923959

SCHEMBL30923959

CCS(=O)(=O)N[C@@H]1CN(C(=O)OC(C)(C)C)[C@H](COCc2ccccc2)C1(F)F

nearest known ligand 0.40

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ STS P08842 1/20 0.40
▸ NR1H2 P55055 6/20 0.39
▸ NR1H3 Q13133 4/20 0.39
▸ GHSR Q92847 4/20 0.38
▸ GPR119 Q8TDV5 1/20 0.36
▸ HCRTR2 O43614 1/20 0.36
▸ PARP1 P09874 1/20 0.35
▸ TACR1 P25103 1/20 0.35
▸ KLK7 P49862 1/20 0.35
▸ PTPN1 P18031 1/20 0.35
▸ ABCB1 P08183 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30924048 0.92 HCRTR2 (0.42) STSNR1H2NR1H3GHSRGPR119
SCHEMBL30924050 0.92 HCRTR2 (0.42) STSNR1H2NR1H3GHSRGPR119
SCHEMBL30923947 0.90 NR1H2 (0.40) STSNR1H2NR1H3GHSRHCRTR2
SCHEMBL27219995 0.88 MMP1 (0.36) HCRTR2PTPN1
SCHEMBL30924028 0.82 NR1H2 (0.39) STSNR1H2NR1H3GHSRPARP1
SCHEMBL30923948 0.81 PARP1 (0.40) STSNR1H2NR1H3GHSRPARP1
SCHEMBL30957911 0.81 PARP1 (0.40) STSNR1H2NR1H3GHSRPARP1
SCHEMBL27220018 0.79 MMP1 (0.36) HCRTR2TACR1
SCHEMBL30924012 0.78 NR1H2 (0.34) NR1H2PTPN1
SCHEMBL27219736 0.78 MMP1 (0.35) HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122071471-A Heterocyclic compounds 武田药品工业株式会社 2026-05-22 — — CN disclosed
CN-122010945-A Heterocyclic compounds 武田药品工业株式会社 2026-05-12 — — CN disclosed
CN-122010946-A Heterocyclic compounds 武田药品工业株式会社 2026-05-12 — — CN disclosed
US-12534471-B2 Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2026-01-27 — — US disclosed
EP-4612145-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2025-09-10 — — EP disclosed
US-20240317765-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-09-26 — — US disclosed
US-20240174677-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-05-30 — — US disclosed
WO-2024095133-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317765-A1 HETEROCYCLIC COMPOUND HCRTR2, HCRTR1, NPY2R STS 1342/4885NR1H2 170/4885NR1H3 225/4885
US-20240174677-A1 HETEROCYCLIC COMPOUND HCRTR2, HCRTR1, NPY2R STS 1342/4885NR1H2 170/4885NR1H3 225/4885
US-12534471-B2 Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof HCRTR2, HCRTR1, NPY1R STS 3707/4885NR1H2 79/4885NR1H3 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.